Spark Therapeutics Inc. (ONCE) 61.39 $ONCE
IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
at The Street - Fri Apr 17, 10:28AM CDT
Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?
XBIT: 22.94 (-4.50), VIRT: 22.16 (-0.44), SHAK: 68.53 (+5.80), BOX: 17.75 (-0.53), ADRO: 36.00 (-0.39), ONCE: 61.39 (-0.66), CDTX: 15.10 (-0.05), ETSY: 25.58 (-0.04), CPPL: 26.52 (-0.39), SMMT: 10.30 (-0.20), LENS: 7.38 (-0.62), NVET: 8.70 (-0.11), GDDY: 25.63 (+0.58)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.01 (-0.95), KITE: 60.58 (-0.35), CYBR: 66.78 (+0.16), ONCE: 61.39 (-0.66), ATRA: 59.89 (-4.13)
Floats Stumble In Q1 As Bubble Debate Escalates
EP Vantage - Seeking Alpha - Mon Apr 13, 1:15PM CDT
In the “it is/is not a bubble” debate, those arguing “is” have a data point on their side with the news that first-quarter biopharma flotation totals were among the most disappointing in two years. It might be too soon to...
GILD: 103.69 (-1.52), ITEK: 5.61 (+0.86), ONCE: 61.39 (-0.66), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98)
Biotech Stocks Still Feeling Healthy Despite Bubble Talk
at The Street - Mon Apr 06, 4:20PM CDT
Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.
JNJ: 101.08 (+0.62), BIIB: 401.71 (-28.57), BMRN: 120.28 (-2.67), ONCE: 61.39 (-0.66), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), XLV: 74.39 (-0.24)
Here Are The Top Performing IPOs In The First Quarter
at Investor's Business Daily - Fri Apr 03, 7:02AM CDT
The health care sector, which had the most initial public offerings of 2014, continued a hot pace in the first quarter. Spark Therapeutics (ONCE) was the top IPO winner in the first quarter, with a 237% return. The biotech developer of gene therapy...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), TCON: 11.74 (-0.41)
Nasdaq Leads U.S. Exchanges for IPOs in 2015
GlobeNewswire - Wed Apr 01, 11:06AM CDT
Nasdaq (Nasdaq:NDAQ) announced that it welcomed 43 new listings, including 27 initial public offerings (IPOs) on The Nasdaq Stock Market in the first quarter of 2015, more than double the number of IPOs of any other U.S. exchange. Combined proceeds raised by Nasdaq's first quarter IPOs totaled approximately $2.8 billion. Nasdaq remains the leading U.S. exchange for healthcare, financial and venture capital-backed IPOs and welcomed the largest technology deal year-to-date with Inovalon Holdings (Nasdaq:INOV). In the first quarter Nasdaq's IPOs have returned on average an increase of 23 percent from their offer price, above the market average return for all U.S. IPOs of 21 percent.
SEDG: 24.89 (+0.10), AMD: 2.30 (-0.03), ONCE: 61.39 (-0.66), CLLS: 32.61 (-0.07), INOV: 26.67 (-0.32), NDAQ: 48.57 (-1.19), TW: 128.79 (-0.36)
Renaissance Capital's Q1 2015 U.S. IPO Market Review
Renaissance Capital IPO Research - at Seeking Alpha - Tue Mar 31, 6:35PM CDT
2015 US IPO Market Off to a Slow Start After a record year in 2014, the IPO market slowed dramatically in the first quarter of 2015. The 34 IPOs raised $5.4 billion, making it the least active quarter by IPO count since 1Q 2013 and the smallest by...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), HDP: 21.48 (-0.49), HABT: 34.51 (+0.56), INOV: 26.67 (-0.32), CPPL: 26.52 (-0.39), MXPT: 7.80 (-0.08), NEWR: 32.68 (-0.28), ZOES: 34.67 (+0.83), HLT: 30.28 (-0.03), ONCE: 61.39 (-0.66), SUM: 23.73 (+0.66), LOCO: 28.00 (unch), JD: 34.72 (+1.06), TWTR: 50.82 (-0.59), LENS: 7.38 (-0.62), GDDY: 25.63 (+0.58)
IPO Market Ends Quarter At Lowest Level In Two Years
at Investor's Business Daily - Tue Mar 31, 12:44PM CDT
After a record 2014, the U.S. IPO market slowed sharply in the first quarter, with its lowest number of initial public offerings in two years. The 34 IPOs in Q1 raised $5.4 billion, marking the fewest IPOs since since Q1 2013 and the smallest in...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), HABT: 34.51 (+0.56), GDDY: 25.63 (+0.58)
Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
DoconStocks - at Seeking Alpha - Tue Mar 31, 7:48AM CDT
BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)
Spark Therapeutics, Inc. (Nasdaq: ONCE) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Mar 27, 9:00AM CDT
What:
ONCE: 61.39 (-0.66), NDAQ: 48.57 (-1.19)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)
Earnings Estimates Moving Higher for Spark Therapeutics (ONCE): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:44AM CDT
Spark Therapeutics in the health care space is seeing solid activity on the earnings estimate revision front
ONCE: 61.39 (-0.66)
Spark Therapeutics (ONCE) in Focus: Stock Tumbles 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:58AM CDT
Although the slump was obviously disappointing, current year consensus estimate trend of Spark Therapeutics (ONCE) has moved higher over the past few weeks
ABAX: 63.62 (+0.31), ONCE: 61.39 (-0.66)
Spark Therapeutics Reports Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 18, 7:09AM CDT
Spark Therapeutics (Nasdaq:ONCE) today announced financial results for the year ended December 31, 2014.
ONCE: 61.39 (-0.66)
Spark Therapeutics beats by $0.94
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 7:05AM CDT
ONCE: 61.39 (-0.66)
'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley
at The Street - Tue Mar 17, 5:00AM CDT
Cramer wants you to avoid Pacific Ethanol, Sanchez Energy and Micron but buy, buy, buy Alcoa.
MU: 29.20 (-0.31), AA: 13.22 (+0.03), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), TRN: 28.70 (-4.66), ICPT: 283.20 (-2.22), SN: 13.58 (-0.05), RRD: 19.30 (-0.40), PEIX: 12.03 (-0.41), VZ: 50.03 (-0.02), VOD: 35.20 (+0.52), HRB: 32.26 (-0.38)
PC Related Means Sell - Cramer's Lightning Round (3/16/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Mar 17, 4:58AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 16. Bullish Calls: H&R Block (NYSE: HRB ): "I think the earnings are going to be consistent. I like this year for them when they can return...
MU: 29.20 (-0.31), AA: 13.22 (+0.03), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), TRN: 28.70 (-4.66), ICPT: 283.20 (-2.22), SN: 13.58 (-0.05), RRD: 19.30 (-0.40), PEIX: 12.03 (-0.41), VZ: 50.03 (-0.02), VOD: 35.20 (+0.52), HRB: 32.26 (-0.38)
Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market
at The Street - Mon Mar 16, 7:15PM CDT
It's creating investment opportunities that just shouldn't exist, Cramer says.
KMI: 44.34 (-0.23), TSLA: 218.43 (-0.17), BIIB: 401.71 (-28.57), MMM: 158.99 (-0.67), ACT: 295.41 (-2.95), SHAK: 68.53 (+5.80), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), NBR: 15.04 (-0.53), SLG: 128.82 (+1.47), RRD: 19.30 (-0.40), CFN: 59.91 (-0.06), TRN: 28.70 (-4.66), CMG: 637.50 (+1.90), HBI: 32.22 (-2.36), DNR: 8.10 (-0.31), PEIX: 12.03 (-0.41), OA: 72.91 (-1.33), HSIC: 142.54 (+0.70), REGN: 480.09 (+0.01), CSCO: 28.82 (+0.15), HRB: 32.26 (-0.38), HYH: 49.27 (+0.09), MU: 29.20 (-0.31), AVP: 9.02 (+0.03), HAR: 145.10 (-1.39), ETN: 68.58 (-0.52), EW: 138.33 (-3.59), DIS: 109.53 (+0.53), AMGN: 167.91 (-1.26), SN: 13.58 (-0.05), BA: 148.40 (-1.47), VOD: 35.20 (+0.52), AA: 13.22 (+0.03), EQIX: 246.07 (-0.86), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), ICPT: 283.20 (-2.22), ULTA: 157.08 (+0.09), VZ: 50.03 (-0.02)
Biogen's hemophilia B med successful in Phase 3 trial in children
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:59AM CST
BIIB: 401.71 (-28.57), ALNY: 119.01 (+0.29), OPK: 14.83 (+0.17), ONCE: 61.39 (-0.66), BAX: 71.14 (-0.37), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), SGMO: 14.70 (-0.84)
Stocks Edge Lower, Oil Falls, But Managed-Care Firms Shine
at Investor's Business Daily - Mon Feb 23, 10:47AM CST
Stocks kicked off the week with modest losses Monday on a generally quiet day of news flow. The Dow Jones industrial average eased 0.2% while the S&P 500 and Nasdaq lost 0.1% each. NYSE and Nasdaq volume was tracking slightly lower than Friday's...
CNC: 73.67 (+1.13), UA: 82.56 (-0.70), INSY: 62.42 (-1.90), VRX: 210.42 (+1.03), PCYC: 256.59 (-0.51), ONCE: 61.39 (-0.66), ORLY: 229.35 (+1.04), SLXP: 172.96 (+0.15), PCRX: 85.07 (+0.80), HUM: 182.35 (+0.44)
IPO Market 'Has Been a Lonely Place' but Pace Is Picking Up
at The Street - Fri Apr 17, 10:28AM CDT
Etsy and Virtu made a quite a splash with their Nasdaq debuts this week but is it enough to bring the U.S. IPO market out of its 2015 lull?
XBIT: 22.94 (-4.50), VIRT: 22.16 (-0.44), SHAK: 68.53 (+5.80), BOX: 17.75 (-0.53), ADRO: 36.00 (-0.39), ONCE: 61.39 (-0.66), CDTX: 15.10 (-0.05), ETSY: 25.58 (-0.04), CPPL: 26.52 (-0.39), SMMT: 10.30 (-0.20), LENS: 7.38 (-0.62), NVET: 8.70 (-0.11), GDDY: 25.63 (+0.58)
The Top 5 Best IPO Performers in the Last Year
at The Street - Thu Apr 16, 2:56PM CDT
These are the top five best IPO performers in the last 12 months.
RDUS: 41.01 (-0.95), KITE: 60.58 (-0.35), CYBR: 66.78 (+0.16), ONCE: 61.39 (-0.66), ATRA: 59.89 (-4.13)
Floats Stumble In Q1 As Bubble Debate Escalates
EP Vantage - Seeking Alpha - Mon Apr 13, 1:15PM CDT
In the “it is/is not a bubble” debate, those arguing “is” have a data point on their side with the news that first-quarter biopharma flotation totals were among the most disappointing in two years. It might be too soon to...
GILD: 103.69 (-1.52), ITEK: 5.61 (+0.86), ONCE: 61.39 (-0.66), XBI: 233.86 (-2.86), IBB: 363.70 (-3.98)
Biotech Stocks Still Feeling Healthy Despite Bubble Talk
at The Street - Mon Apr 06, 4:20PM CDT
Shareholders feeling vertigo following the steep run-up in healthcare and biotech stocks need not reach for the medicine cabinet or the exit, says Marshall Gordon, Research Analyst at ClearBridge Investments.
JNJ: 101.08 (+0.62), BIIB: 401.71 (-28.57), BMRN: 120.28 (-2.67), ONCE: 61.39 (-0.66), PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), ABBV: 66.07 (+1.82), BMY: 65.80 (-0.20), XLV: 74.39 (-0.24)
Here Are The Top Performing IPOs In The First Quarter
at Investor's Business Daily - Fri Apr 03, 7:02AM CDT
The health care sector, which had the most initial public offerings of 2014, continued a hot pace in the first quarter. Spark Therapeutics (ONCE) was the top IPO winner in the first quarter, with a 237% return. The biotech developer of gene therapy...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), ENTL: 27.43 (+0.44), TCON: 11.74 (-0.41)
Nasdaq Leads U.S. Exchanges for IPOs in 2015
GlobeNewswire - Wed Apr 01, 11:06AM CDT
Nasdaq (Nasdaq:NDAQ) announced that it welcomed 43 new listings, including 27 initial public offerings (IPOs) on The Nasdaq Stock Market in the first quarter of 2015, more than double the number of IPOs of any other U.S. exchange. Combined proceeds raised by Nasdaq's first quarter IPOs totaled approximately $2.8 billion. Nasdaq remains the leading U.S. exchange for healthcare, financial and venture capital-backed IPOs and welcomed the largest technology deal year-to-date with Inovalon Holdings (Nasdaq:INOV). In the first quarter Nasdaq's IPOs have returned on average an increase of 23 percent from their offer price, above the market average return for all U.S. IPOs of 21 percent.
SEDG: 24.89 (+0.10), AMD: 2.30 (-0.03), ONCE: 61.39 (-0.66), CLLS: 32.61 (-0.07), INOV: 26.67 (-0.32), NDAQ: 48.57 (-1.19), TW: 128.79 (-0.36)
Renaissance Capital's Q1 2015 U.S. IPO Market Review
Renaissance Capital IPO Research - at Seeking Alpha - Tue Mar 31, 6:35PM CDT
2015 US IPO Market Off to a Slow Start After a record year in 2014, the IPO market slowed dramatically in the first quarter of 2015. The 34 IPOs raised $5.4 billion, making it the least active quarter by IPO count since 1Q 2013 and the smallest by...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), HDP: 21.48 (-0.49), HABT: 34.51 (+0.56), INOV: 26.67 (-0.32), CPPL: 26.52 (-0.39), MXPT: 7.80 (-0.08), NEWR: 32.68 (-0.28), ZOES: 34.67 (+0.83), HLT: 30.28 (-0.03), ONCE: 61.39 (-0.66), SUM: 23.73 (+0.66), LOCO: 28.00 (unch), JD: 34.72 (+1.06), TWTR: 50.82 (-0.59), LENS: 7.38 (-0.62), GDDY: 25.63 (+0.58)
IPO Market Ends Quarter At Lowest Level In Two Years
at Investor's Business Daily - Tue Mar 31, 12:44PM CDT
After a record 2014, the U.S. IPO market slowed sharply in the first quarter, with its lowest number of initial public offerings in two years. The 34 IPOs in Q1 raised $5.4 billion, marking the fewest IPOs since since Q1 2013 and the smallest in...
BOX: 17.75 (-0.53), SHAK: 68.53 (+5.80), ONCE: 61.39 (-0.66), HABT: 34.51 (+0.56), GDDY: 25.63 (+0.58)
Celladon: The Next Breakthrough In Cardiovascular Gene Therapy?
DoconStocks - at Seeking Alpha - Tue Mar 31, 7:48AM CDT
BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)
Spark Therapeutics, Inc. (Nasdaq: ONCE) to Ring The Nasdaq Stock Market Opening Bell
GlobeNewswire - Fri Mar 27, 9:00AM CDT
What:
ONCE: 61.39 (-0.66), NDAQ: 48.57 (-1.19)
Celladon Heart-Failure Study Looms Large as Next Big Test for Gene Therapy
at The Street - Wed Mar 25, 9:06AM CDT
In April, Celladon is expecting results from a mid-stage study of a gene therapy aiming to improve the pumping ability of the heart in patients with advanced heart failure.
BLUE: 136.26 (-3.82), ONCE: 61.39 (-0.66), CLDN: 13.68 (-0.26)
Earnings Estimates Moving Higher for Spark Therapeutics (ONCE): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 25, 7:44AM CDT
Spark Therapeutics in the health care space is seeing solid activity on the earnings estimate revision front
ONCE: 61.39 (-0.66)
Spark Therapeutics (ONCE) in Focus: Stock Tumbles 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 23, 7:58AM CDT
Although the slump was obviously disappointing, current year consensus estimate trend of Spark Therapeutics (ONCE) has moved higher over the past few weeks
ABAX: 63.62 (+0.31), ONCE: 61.39 (-0.66)
Spark Therapeutics Reports Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 18, 7:09AM CDT
Spark Therapeutics (Nasdaq:ONCE) today announced financial results for the year ended December 31, 2014.
ONCE: 61.39 (-0.66)
Spark Therapeutics beats by $0.94
Seeking Alpha - at Seeking Alpha - Wed Mar 18, 7:05AM CDT
ONCE: 61.39 (-0.66)
'Mad Money' Lightning Round: I LIke H&R Block, RR Donnelley
at The Street - Tue Mar 17, 5:00AM CDT
Cramer wants you to avoid Pacific Ethanol, Sanchez Energy and Micron but buy, buy, buy Alcoa.
MU: 29.20 (-0.31), AA: 13.22 (+0.03), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), TRN: 28.70 (-4.66), ICPT: 283.20 (-2.22), SN: 13.58 (-0.05), RRD: 19.30 (-0.40), PEIX: 12.03 (-0.41), VZ: 50.03 (-0.02), VOD: 35.20 (+0.52), HRB: 32.26 (-0.38)
PC Related Means Sell - Cramer's Lightning Round (3/16/15)
SA Editor Mohit Manghnani - at Seeking Alpha - Tue Mar 17, 4:58AM CDT
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Monday, March 16. Bullish Calls: H&R Block (NYSE: HRB ): "I think the earnings are going to be consistent. I like this year for them when they can return...
MU: 29.20 (-0.31), AA: 13.22 (+0.03), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), TRN: 28.70 (-4.66), ICPT: 283.20 (-2.22), SN: 13.58 (-0.05), RRD: 19.30 (-0.40), PEIX: 12.03 (-0.41), VZ: 50.03 (-0.02), VOD: 35.20 (+0.52), HRB: 32.26 (-0.38)
Jim Cramer's 'Mad Money' Recap: This Is One Stupid Market
at The Street - Mon Mar 16, 7:15PM CDT
It's creating investment opportunities that just shouldn't exist, Cramer says.
KMI: 44.34 (-0.23), TSLA: 218.43 (-0.17), BIIB: 401.71 (-28.57), MMM: 158.99 (-0.67), ACT: 295.41 (-2.95), SHAK: 68.53 (+5.80), PCYC: 256.59 (-0.51), BMRN: 120.28 (-2.67), NBR: 15.04 (-0.53), SLG: 128.82 (+1.47), RRD: 19.30 (-0.40), CFN: 59.91 (-0.06), TRN: 28.70 (-4.66), CMG: 637.50 (+1.90), HBI: 32.22 (-2.36), DNR: 8.10 (-0.31), PEIX: 12.03 (-0.41), OA: 72.91 (-1.33), HSIC: 142.54 (+0.70), REGN: 480.09 (+0.01), CSCO: 28.82 (+0.15), HRB: 32.26 (-0.38), HYH: 49.27 (+0.09), MU: 29.20 (-0.31), AVP: 9.02 (+0.03), HAR: 145.10 (-1.39), ETN: 68.58 (-0.52), EW: 138.33 (-3.59), DIS: 109.53 (+0.53), AMGN: 167.91 (-1.26), SN: 13.58 (-0.05), BA: 148.40 (-1.47), VOD: 35.20 (+0.52), AA: 13.22 (+0.03), EQIX: 246.07 (-0.86), ISIS: 66.37 (-1.38), ONCE: 61.39 (-0.66), ICPT: 283.20 (-2.22), ULTA: 157.08 (+0.09), VZ: 50.03 (-0.02)
Biogen's hemophilia B med successful in Phase 3 trial in children
Seeking Alpha - at Seeking Alpha - Fri Feb 27, 8:59AM CST
BIIB: 401.71 (-28.57), ALNY: 119.01 (+0.29), OPK: 14.83 (+0.17), ONCE: 61.39 (-0.66), BAX: 71.14 (-0.37), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), SGMO: 14.70 (-0.84)
Stocks Edge Lower, Oil Falls, But Managed-Care Firms Shine
at Investor's Business Daily - Mon Feb 23, 10:47AM CST
Stocks kicked off the week with modest losses Monday on a generally quiet day of news flow. The Dow Jones industrial average eased 0.2% while the S&P 500 and Nasdaq lost 0.1% each. NYSE and Nasdaq volume was tracking slightly lower than Friday's...
CNC: 73.67 (+1.13), UA: 82.56 (-0.70), INSY: 62.42 (-1.90), VRX: 210.42 (+1.03), PCYC: 256.59 (-0.51), ONCE: 61.39 (-0.66), ORLY: 229.35 (+1.04), SLXP: 172.96 (+0.15), PCRX: 85.07 (+0.80), HUM: 182.35 (+0.44)
